School of Medicine
Showing 1-10 of 41 Results
Professor of Pediatrics (Endocrinology) at the Lucile Salter Packard Children's Hospital and at the Stanford University Medical Center
Bio In 2016 I moved to become Professor of Pediatrics and Division Chief of Pediatric Endocrinology at Stanford University. My research interest is to improve care and prevent complications in people with type 1 diabetes (T1D). I was co-author with Dr Peter Chase on the 12th and 13th editions of Understanding Diabetes, or Pink Panther education books. Specifically, my research has extended from epidemiologic studies identifying targets to development of clinical trials to test interventions. My NIDDK sponsored K23 ?Cardiovascular Disease in Type 1 Diabetes Mellitus: Young Adults to Adolescents? focused on cardiovascular and kidney complications in young adults with T1D. I continued this work as part of the Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study with Drs. Marian Rewers and Janet Snell-Bergeon and in the pediatric population with Dr. Paul Wadwa and as investigator with the Search for Diabetes in Youth study. I am a past co-Chair for Protocols and Publications with the Type 1 Diabetes Exchange and continue as a Steering Committee member and director of international collaborations which complements my role as Secretary-General for ISPAD. While in Colorado I was local PI on PERL, an RCT to prevent early kidney function decline with Drs Michael Mauer (UMinnesota) and Alessandro Doria (Joslin) as PIs. I am a PI on FL3X, an innovative behavioral intervention for adolescents with T1D with Drs. Elizabeth Mayer-Davis (UNC) and Michael Seid (Cincinnati). As a logical extension of this research to prevent T1D complications, my research has increasingly focused on the development of the artificial pancreas as improved glucose control is the best proven method to prevent T1D complications. In Colorado I was the local PI on 3 UC4 funded artificial pancreas studies and I continue this research at Stanford with Drs Bruce Buckingham and Korey Hood. I work with clinical and engineering collaborators at RPI, JAEB, Sansum/UCSB, Yale, UVa, Cambridge, Boston University, and UC-Boulder on JDRF, NIDDK, and NSF funded studies as listed below. I was co-PI with Dr. Klingensmith on the Barbara Davis Center T32 and K12 training grants in Pediatric Endocrinology. I am Associate Director of the Stanford University Diabetes Research Center with Drs Seung Kim (Director) and Frederic Kraemer https://sdrc.stanford.edu .
Professor of Pediatrics (Hematology/Oncology) and of Medicine
Current Research and Scholarly Interests Recent clinical studies, by us and others, have demonstrated that T cell based immunotherapy can eradicate cancers resistant to all other available therapies. Our program is focused on using genetically engineered T cells to treat cancer. We link the bench with the bedside, developing novel therapies for early phase testing in clinical trials, will simultaneously conducting intensive studies on clinical samples obtained from patients treated on immunotherapy trials.
David Magnus, Ph.D.
Thomas A. Raffin Professor in Medicine and Biomedical Ethics, Professor (Teaching) of Medicine (General Medical Disciplines) and, by courtesy, of Bioengineering
Current Research and Scholarly Interests Genetic testing, gene therapy, genetically engineered organisms, and the history of eugenics. Stem cell research and cloning, and egg procurement. Examining ethical issues in reproductive technologies. Organ transplantation including donation after cardiac death, ethics of listing decisions. End of life issues in both adults and children.
Instructor, Pediatrics - Hematology & Oncology
Bio Robbie Majzner is an Instructor in the Division of Pediatric Hematology-Oncology at the Stanford University School of Medicine. After graduating with a BA in computer science from Columbia University, Dr. Majzner attended Harvard Medical School where he developed an interest in pediatric oncology. He completed his residency training in pediatrics at New York Presbyterian-Columbia and fellowship training in pediatric hematology-oncology at Johns Hopkins and the National Cancer Institute. During his fellowship, he began working in the laboratory of Crystal Mackall with the goal of translating the success seen with CD19 chimeric antigen receptor (CAR) T cells to pediatric solid tumors.
Dr. Majzner has generated novel CAR T cells against anaplastic lymphoma kinase (ALK), B7-H3 (CD276), and GD2. His work on the ALK CAR demonstrated that unlike native T cell receptors, synthetic CARs require high antigen density for in vivo efficacy. Using the gold standard CD19 CAR, he is continuing to probe the contribution of antigen density to CAR efficacy, and has reengineered CARs to function at lower antigen densities. He has also generated and validated a novel CAR against B7-H3, a pan-cancer antigen broadly expressed on pediatric tumors, which demonstrates exciting preclinical activity in pediatric sarcomas and brain tumors. Through his research, he aims to bring advances in cell therapy to children with incurable cancers. Clinically, Dr. Majzner cares for patients with neuroblastoma and other solid tumors. He is board certified in pediatrics and pediatric hematology-oncology.
Senior Associate Dean, Faculty Development and Diversity and Professor of Pediatrics (Infectious Diseases)
Current Research and Scholarly Interests My research focuses on epidemiologic aspects of viral vaccines and perinatal HIV infection. This includes the molecular epidemiology of factors affecting the immunogenicity of oral polio vaccine (OPV) in developing areas of the world, and now the epidemiology of transmission and circulation of vaccine derived polioviruses in order to assist in global eradication of polio. I also work in development of methods to prevent breastfeeding transmission of HIV in Africa.
Professor of Pediatrics (Hematology/Oncology) at the Lucile Salter Packard Children's Hospital, Emerita
Current Research and Scholarly Interests Germ cell tumors and bone sarcomas.